Fermenta Biotech
- Market cap
- ₹ 1,342 Cr.
- P/E
- 23.9x
- P/B
- 3.24x
- 52-week range
- 248.85 – 582.65
- ROE
- 16%
- ROCE
- 21%
- Dividend yield
- 0.8%
- Debt / equity
- 0.28
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Fermenta Biotech Limited is an India-based company that is engaged in the manufacturing of vitamin D, active pharmaceutical ingredients (APIs), enzymes and providing environmental solutions services. It is also engaged in renting and selling properties. Its segments include Chemicals/Bulk Drug and Property. The Chemicals/Bulk Drug segment is engaged in the manufacturing and selling of chemicals, primarily bulk drugs and enzymes. The Property segment is involved in renting and sale of properties. It has a diverse range of products and services that cater to various industries, such as pharmaceuticals, dietary and nutritional supplements, food and beverage fortification, animal feed, veterinary and others. It provides proprietary specialized technologies through its enzyme portfolio across the biopharmaceutical product life cycle. It also offers a range of nutritional ingredients, such as fish oil-derived cholesterol for aquaculture nutrition, and vitamin AD2 premix, among others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Fermenta Biotech against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)23.9 against a typical 34: cheaper than most peers (1st = cheapest).78th of 220
- Sales growth−10.6% against a typical +15.6% from a year earlier.165th of 197
- Profit growth−55.9% against a typical +18.9% from a year earlier.136th of 160
- Share price, 3 months−0.6% against a typical −0.5%.103rd of 200
- Size₹ 1,342.4 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).82nd of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Moderate safety, with caution
Rated BBB+ by CARE- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE BBB+ | Stable | 20 Aug 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 20 Aug 2026 | ▲ Upgrade1 notch | CARE BBB → CARE BBB+ | — | CARE | ₹ 172.98 Cr. | |
| 1 Oct 2025 | ▲ Upgrade | CARE BBB | — | CARE | ₹ 125.19 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 11 Aug 2026 | Financial Results | To consider and approve the unaudited financial results (standalone and consolidated) for the quarter ended Jun 30, 2026. |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 57 | 99 | 97 | 78 | 95 | 156 | 140 | 136 | 130 | 137 | 122 | 122 |
| Expenses | 71 | 74 | 92 | 77 | 76 | 103 | 103 | 108 | 104 | 112 | 102 | 104 |
| Operating Profit | −14 | 25 | 5 | 1 | 19 | 53 | 37 | 28 | 27 | 25 | 20 | 18 |
| OPM % | −24.4% | 25.4% | 5.5% | 1% | 19.8% | 34% | 26.4% | 20.7% | 20.5% | 18.2% | 16.5% | 14.8% |
| Other Income | −6 | 3 | 5 | 3 | 3 | 2 | 4 | 9 | 5 | 1 | 14 | 4 |
| Interest | 4 | 5 | 3 | 3 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 |
| Depreciation | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 5 | 5 | 5 | 5 |
| Profit before tax | −29 | 16 | 1 | −6 | 12 | 45 | 32 | 28 | 24 | 17 | 26 | 15 |
| Tax % | 0% | 37.8% | 884.6% | 0% | 5.9% | 16.4% | −4.2% | 23.1% | 25.2% | 31.2% | 29% | 35.1% |
| Net Profit | −29 | 10 | −7 | −6 | 11 | 38 | 33 | 22 | 18 | 12 | 19 | 10 |
| EPS in Rs | −9.7 | 3.35 | −2.36 | −1.98 | 3.87 | 12.54 | 11.68 | 7.42 | 6.14 | 4.31 | 6.52 | 3.31 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 13%
- 5 Years
- 7%
- 3 Years
- 14%
- TTM
- −3%
- 10 Years
- 51%
- 5 Years
- 7%
- 3 Years
- 65%
- TTM
- −48%
- 10 Years
- 23%
- 5 Years
- 10%
- 3 Years
- 45%
- TTM
- —
- 10 Years
- 13%
- 5 Years
- 7%
- 3 Years
- 13%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Fermenta Biotech | ₹ 448.90 | ₹ 1,342 Cr. | 23.9x | 3.2x | 16% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Prashant Nagre
- Chief Executive Officer, Managing Director, Director
- Krishna Datla
- Executive Vice Chairman of the Board
- Sumesh Gandhi
- Chief Financial Officer
- Anupama Datla Desai
- Executive Director
- Satish Varma
- Executive Director
- Varadvinayak Vijay Khambete
- Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.